Swiss Novartis has announced plans to establish a flagship manufacturing hub in North Carolina, marking a significant expansion of its U.S. operations. The project, which is part of the company’s broader $23 billion investment in U.S. infrastructure, will include new facilities in Durham and Morrisville, expanded capabilities at the existing Durham site, and end-to-end manufacturing across several therapeutic areas.
📍 700,000+ sq ft of manufacturing space
👩🔬 700 new jobs by 2030
🏭 Strengthening the U.S. supply chain and accelerating access to key medicines
North Carolina continues to reinforce its position as a leader in advanced pharmaceutical manufacturing, backed by world-class talent, innovation, and a thriving life sciences ecosystem.
Congratulations to the Economic Development Partnership of North Carolina Team and all partners involved in supporting this milestone investment.
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
